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ABSTRACT 
This paper provides practical guidance on the fundamentals of design for major randomized 
controlled trials. Topics covered include the choice of patients, choice of treatment and control 
groups, choice of primary and secondary endpoints, methods of randomization, appropriate use 
of blinding, and determination of trial size. Insights are made with reference to contemporary 
major trials in cardiology.  
 
<KW> Key words: patient selection; treatment choice; appropriate outcomes; random allocation; 
randomized controlled trials as topic; blinding; sample size 
 
Abbreviations 
ACS = acute coronary syndrome 
CV = cardiovascular 
MACE = major adverse cardiovascular event 
MI = myocardial infarction 
NSTEMI = non-ST-segment elevation myocardial infarction 
PCI = percutaneous coronary intervention 
STEMI = ST-segment elevation myocardial infarction 
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Introduction 
The properly designed randomized controlled trial is recognized as providing the highest level of 
evidence in determining guidelines for therapeutic practice (1). However, numerous pitfalls in 
trial design may occur, which, if succumbed to, may seriously impair the reliability of or 
confidence in the results. In this paper, we review the key features that determine whether a 
trial’s design is “up to scratch.” These fundamentals include: selection of patients, treatments and 
outcomes; randomization methods; appropriate blinding; and determination of trial size. Of 
course, one first has to propose a relevant clinical question for which true equipoise exists. 
Our focus is on major, pivotal (phase III) trials that are intended to directly influence 
clinical practice, and throughout we bring the issues to life with topical examples from recent 
cardiology trials. Our underlying intent is to elucidate matters of trial design that should be 
considered and clearly documented in a study protocol (2,3). Once the study protocol is 
finalized, it is good practice to register the trial on a website (prior to patient enrollment) and to 
make the protocol readily available. The core goals are to plan each trial so that it will achieve 
unbiased conclusions for treatment comparisons of direct public health relevance that are both 
clinically meaningful and statistically precise. It is fundamentally important to differentiate a 
statistically significant difference from a clinically meaningful difference. Very large studies 
may sometimes result in small, statistically significant differences in outcomes that have little or 
no clinical relevance. It is, of course, also essential that the trial can be successfully completed. 
That is, from ethical, scientific, organizational, and funding standpoints, the protocol is 
deliverable. This pragmatism underpins all that follows here.  
Choice of Patients and Centers 
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The delineation of precise eligibility criteria is important in determining the population of 
patients to which the trial findings can be extrapolated (3). Setting the criteria too specifically 
can inhibit successful patient recruitment and restrict generalizability, whereas unduly broad 
entry criteria may dilute the opportunity to identify a treatment effect in a specific population. 
In acute coronary syndromes (ACS), the PLATO trial of ticagrelor versus clopidogrel 
studied a broad population: patients with ACS with or without ST-segment elevation and treated 
with or without invasive procedures (4). In contrast, the HORIZONS-AMI trial compared 
anticoagulation regimens only in patients undergoing primary percutaneous coronary 
intervention (PCI) in acute myocardial infarction (MI) (5). This was appropriate, as the ACUITY 
trial had already studied bivalirudin in ACS patients with high-risk unstable angina or non-ST-
segment elevation MI (NSTEMI) (6). As the prognosis and treatment pathways for patients with 
ACS with and without ST-segment elevation are quite different, it is advisable to avoid pooling 
these 2 groups in a single trial design, unless each cohort is separately powered for safety and 
efficacy. 
In chronic heart failure, the CHARM trial of candesartan had broad entry criteria, with no 
entry ejection fraction restriction, although recognizing that patients with preserved left 
ventricular systolic function should be interpreted as a separate stratum, CHARM PRESERVED 
(7,8). In contrast, the RALES trial of spironolactone focused on high-risk patients (history of 
New York Heart Association class IV and ejection fraction ≤35%). This facilitated using all-
cause mortality as a realistic primary endpoint, but restricted the generalizability of the trial 
findings (9). Alternatively, some trials recruit only high-risk patients in order to achieve a 
sufficient number of outcome events; for example, SAVOR and other cardiovascular (CV) safety 
trials in diabetes (10). 
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Nearly all major trials in cardiology are multicenter, and many have a global recruitment 
strategy. The occasional exception happens  (e.g., the single-center TAPAS and HEAT-PPCI 
trials in ST-segment elevation MI (STEMI) patients)(11,12), but then their generalizability is 
uncertain. The results of single-center trials may be unique to the specific practices and 
techniques employed at that institution; adequate masking and absence of independent 
monitoring and core laboratories may be issues; resource commitment is often less than in 
multicenter trials; and treatment effect sizes can sometimes be at odds with multicenter 
investigations. 
However, global trials raise other issues: problems of ensuring trial quality in all 
countries; issues with center to center variability and training; easier recruitment in certain 
regions (e.g., Eastern Europe), which affects the distribution of geographic representation; and 
concerns over geographic heterogeneity in treatment effect, as occurred in the TOPCAT trial of 
spironolactone in preserved cardiac function heart failure (Figure 1) (13). Nonetheless, large-
scale multicenter trials are preferable to single-center studies, with the understanding that the 
results apply to the geographies and practices of the participants. Secondary analysis should be 
undertaken to ensure there are no major geographic disparities in the results (14). 
Choice of Treatments and Control Groups 
In drug trials, usually the new treatment has 1 specific dose regimen selected on the basis 
of earlier research investigating the agent’s safety profile, and often using surrogate endpoints to 
evaluate efficacy. Occasionally, a major trial proceeds with 2 different doses of the new drug; for 
example, RE-LY in atrial fibrillation and PEGASUS in the post-MI setting (15,16). If the 
increase in trial size necessitated by 2 experimental drug regimens is achievable (with 
appropriate adjustments to preserve alpha), examining different drug doses (or, occasionally, 
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even different experimental treatments) is, in principle, a valuable design option, although 
controversies can ensue in interpretation of findings. 
The appropriate choice of control group is crucial in trial design (17). Many opt for a 
placebo control, whereby the new drug or placebo is assigned on top of current therapeutic 
practice; for example, CHARM and SHIFT (assessing ivabradine) in chronic heart failure (7,18). 
This is common for regulatory trials; evidence for FDA approval can be straightforward, but in 
an advancing field, such as heart failure, it does mean that patients face a growing polypharmacy, 
with little evidence that any drugs get withdrawn from routine use (19). 
Opting for an active comparator poses additional challenges. For example, in the 
PARADIGM-HF trial in heart failure, comparing LCZ696 with enalapril (20), the consequent 
superiority of LCZ696 is liable to have a far greater impact than if a placebo control had been 
chosen. Others will choose an active comparator to demonstrate noninferiority in efficacy, 
anticipating other benefits (e.g., safety). An example is the ACUITY trial in ACS, which 
compared bivalirudin with heparin plus a glycoprotein IIb/IIIa inhibitor (noninferior rates of 
composite adverse ischemic events with reduced major bleeding) (6). A placebo control would 
be unethical in many such scenarios. We review noninferiority trials in next week’s article. 
Another option is to have a third combination treatment arm, new drug + active 
comparator, as was done in the VALIANT trial of valsartan versus enalapril versus both in MI 
with complications (21). In this instance, the combination demonstrated an excess of adverse 
events without improving survival, a warning that combination arms need careful preparatory 
study to see if their safety profiles are acceptable. 
Another consideration for chronic disease trials is whether to have a run-in period prior to 
randomization on either the new drug, the comparator, or both in sequence (as in PARADIGM-
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HF) (20). In principle, this helps to confine enrollment to patients who can tolerate both 
treatments, resulting in greater adherence, but care is needed to ensure that a fair and relevant 
treatment comparison is not compromised. Trials with a run-in period tend to result in better drug 
adherence and tolerability than would otherwise occur. For instance, if a trial of ticagrelor had a 
run-in period, patients experiencing dyspnea in the short-term would likely be excluded, thereby 
under-reporting dyspnea in the consequent randomized comparison. 
Trials comparing radically different strategies, such as PCI versus coronary artery bypass 
graft, face unique challenges, which are discussed in the next article in this series. 
Choice of Primary and Secondary Outcomes 
Most major trials in cardiology focus attention on disease event outcomes. Treatment 
effects on potential surrogate endpoints (22)
 
and biomarkers in earlier-phase trials can be a useful 
motivation and help determine drug dose, but pivotal trials typically require clear evidence of 
patient benefit using clinical endpoints if they are to influence treatment practice. Nonetheless, 
many drugs (and some devices) are approved on the basis of surrogate endpoints (e.g., blood 
pressure or glucose control). Given the cost and complexity of pivotal randomized trials, there is 
increasing interest in considering surrogates as pivotal trial endpoints, but the criteria for true 
surrogacy are difficult, though not impossible, to achieve (23). For example, angiographic late 
loss after coronary stent implantations has been demonstrated to be a surrogate for ischemia-
driven target lesion revascularization (24). 
Although selection of which clinical events to collect follow-up data on may be 
straightforward, precise definitions are needed in the study protocol. Furthermore, many trials 
have an independent Events Adjudication Committee (25) blinded to treatment assignment, a 
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potentially important quality control measure to ensure a greater consistency of event arbitration 
than can be achieved by relying on individual investigators. 
An important challenge is to define the primary endpoint for the trial (26). In trials of 
high-risk patients, such as the PARTNER trials of transaortic valve replacement (27), all-cause 
death is the primary outcome. However, for most major trials, a composite primary endpoint (26) 
comprising several nonfatal events along with mortality is chosen: no one type of event 
adequately captures the treatment effect, and such a composite has the potential to enhance 
statistical power by the greater frequency of patients experiencing at least 1 component of the 
composite during follow-up. 
But what events should contribute to a composite primary endpoint? This depends on the 
disease and treatments being studied. In ACS and diabetes CV safety trials, the usual composite 
is CV death, MI, and stroke. Some are tempted to add in extra components; for example, 
including unstable angina or ischemia-driven revascularization into a broader major adverse CV 
events (MACE) composite. This boosts the numbers of events, but dilutes the impact and 
meaning of the composite. For instance, the most frequent (and often least clinically relevant) 
component tends to be the driver of event rates (e.g., enzymatic MIs or revascularization in ACS 
trials). 
In chronic heart failure, the standard composite primary endpoint is CV death and 
hospitalization for heart failure. The weakness here is that it emphasizes the first hospitalization 
and ignores any subsequent hospitalizations or death thereafter. Greater insight and enhanced 
statistical power may be achieved by a primary endpoint analysis that incorporates both repeat 
hospitalizations for heart failure and CV death (28), as in the ongoing PARAGON trial of 
LCZ696 versus valsartan in preserved ejection fraction heart failure (29).  
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Several options exist for the analysis of repeat events (e.g., hospitalizations) in chronic 
disease (e.g., heart failure) trials and are illustrated in reanalyses of the CHARM and CORONA 
trials (28,30). It is important to recognize that repeat events within a patient are not independent. 
For example, a few patients will have many hospitalizations, whereas many will have none at all. 
The negative binomial approach allows for this, while producing event rates per treatment and 
hence a rate ratio (and its confidence interval). One complexity is the competing risk of 
mortality: patients often have high event rates prior to death, but their follow-up is then 
informatively censored. Joint frailty models can simultaneously estimate both hospitalization and 
mortality risks: the challenge is how to make such statistical complexity comprehensible to 
readers of trial reports with repeat events data. 
Novel methods of handling composite endpoints are of value when the components vary 
in their clinical severity and importance. The least serious component may tend to occur earlier 
(and more frequently), and thus is afforded undue priority in a conventional analysis. These 
novel methods; for example, the Finkelstein-Schoenfeld method or the win ratio, invert the 
priorities to match with clinical severity (31-33). The principle behind the win ratio method is 
that one compares every possible pair of patients on the new treatment and the standard 
treatment. First, the “new” patient is declared the winner or loser if they did better or worse on 
the most serious outcome (e.g., who lived longer). If neither died, then you decide the winner or 
loser on the basis of who had the next most serious outcome (e.g., hospitalization) first and so 
on, if there are more (less-serious) events to help determine who did worse. Then, across all 
pairs, one notes the number of winners and number of losers for the new treatment (ignoring any 
“tied” pairs who had no relevant events): the win ratio is the former number divided by the latter. 
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This concept can be extended to include nonevent outcomes (e.g., ejection fraction), as a “tie-
breaker” in patients who are otherwise event-free.(34) 
Another challenge is how to incorporate predefined safety concerns; for example, major 
bleeding in antiplatelet and anticoagulant drug trials, into the overall outcome priorities. Some 
trials (e.g., ACUITY and OPTIMIZE (6,35)), have extended MACE to net adverse clinical 
events by adding major bleeding as an extra component of the primary composite outcome (26). 
If the included safety and efficacy components are weighted similarly in terms of their clinical 
importance, such an endpoint may reflect the overall net clinical benefit to the patient of the 
therapies being evaluated. However, if adequate power is present, it may be more desirable to 
evaluate efficacy and safety separately, as coprimary endpoints. For example, major bleeding 
was predefined as the primary safety outcome in the HORIZONS-AMI trial (5).  
In general, efforts to collect quality data on potential safety concerns are important. 
Although MedDRA coding of adverse events and serious adverse events is well established (36), 
the process has its limitations. Thus, if prior insight into which safety concerns may plausibly 
arise is available, specific extra reporting procedures may be undertaken for such events. 
Having defined the primary endpoint, it is important to then provide a list of secondary 
endpoints in the protocol, along with any predefined priorities among them. Specifically, the 
separate components of the primary endpoint should be included here. For regulatory trials, 
interest focuses on how to interpret secondary endpoint data, should the primary be “positive”; 
that is, can one extend the label to include any positive secondary endpoints? Across a 
multiplicity of outcomes there are 2 options in this regard. First, one can list a set of secondary 
endpoints in order of priority, so that one can proceed down that list when results are known, 
counting all in sequence as positive until one fails to reach statistical significance (hierarchical 
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testing). Alternatively, one can pre-declare, on equal terms, a specific set of secondary outcomes 
and use a statistical correction for multiplicity (e.g., the Hochberg procedure (37)), in 
determining which endpoints meet criteria as “positive.” If a method to control for multiplicity 
was not pre-specified, the data with confidence intervals should just be presented, and clearly 
identified as secondary outcomes. Although the implications from such secondary endpoints 
should usually be considered exploratory and hypothesis generating, they still may provide a 
persuasive level of evidence if highly positive (e.g., p <0.001). 
Because patient-centered outcomes and economic evaluations are of increasing 
importance, secondary outcomes may also include quality of life, patient preferences, and 
resource utilization data. 
Methods of Randomization 
The justification for randomization, and the problems in interpreting nonrandomized treatment 
comparisons are well known (38,39). Herein, we discuss the actual methods of setting up and 
delivering random allocation of patients to treatments (40).There are 3 key elements: 1) the 
statistical methods used to set up the sequence of randomized treatment assignments; 2) the 
practical means by which the investigator assigns each randomized treatment; and 3) ensuring 
that patient eligibility, investigator agreements, and informed patient consent are all in place 
before randomization. Informed consent is a vital component of ethical trial conduct, but its 
proper delivery lies beyond the scope of this more statistical article. We do note, however, that 
there are special challenges to obtaining consent in an emergency setting; for example, primary 
PCI in STEMI patients. 
A central tenet is that the investigator cannot predict the assignment in advance because 
that could bias the choice of the next patient to be randomized. The CONSORT guidelines state 
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that a trial publication should document these randomization methods (41). For example, the 
MATRIX trial stated: “before start of angiography, patients were centrally assigned (1:1) to 
radial or femoral access... using a web-based system to ensure adequate concealment of 
allocation. The randomized sequence was computer generated, blocked and stratified by... use of 
ticagrelor or prasugrel, type of ACS (STEMI or NSTEMI) and anticipated use of immediate 
PCI” (42). Thus, MATRIX used one of the most common approaches: a web-based allocation 
system and random permuted blocks within strata, with 2 × 2 × 2 = 8 strata in this instance. What 
is not stated here is the number of patients in each randomized block: commonly this is set at 4 
(two per treatment) or 6 (three per treatment) in a random order. Because MATRIX is an “open” 
study, blocks of varying size would be recommended to avoid prediction of some assignments in 
advance, whereas this consideration is less important for blinded trials. 
For the CURRENT-OASIS 7 trial, a 24-h computerized, central automated voice-
response system, with permuted block randomization stratified by center, was used (43). Note 
the need for continuous day and night randomization in an acute setting. 
These 2 examples, 1 stratifying by 3 patient factors (but not center) and the other 
stratifying by center only, reflect the diversity of approaches to stratifying randomization. 
Indeed, some trials (e.g., CHARM in chronic heart failure (7)) have just a simple randomization 
list with permuted blocks. So why stratify at all? Stratification offers insurance that for a key 
patient feature, a serious imbalance between treatment groups will not arise by chance. However, 
for large, pivotal trials, this becomes very unlikely and, if it does occur, it may be accounted for 
in a covariate-adjusted analysis. In addition, trialists often have difficulty agreeing on the choice 
of stratification variables, and the gain in statistical efficiency by stratification is negligible. 
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However, showing near-perfect balance in treatment groups for key baseline variables is a 
convenient bonus of stratification. 
An alternative method of achieving balance across 2 or more baseline features is called 
minimization (44). Minimization is a dynamic approach (randomization lists are not prepared in 
advance) whereby, as each patient enters the trial, a computerized algorithm determines which 
treatment assignment would achieve the better overall balance across multiple patient 
characteristics. That treatment is then assigned, or, to preserve a chance element, it is assigned 
with a high probability (e.g., 0.75). For example, the TITRe2 trial of liberal versus restrictive 
transfusion after cardiac surgery “used cohort minimization to balance assignments according to 
center and type of surgery” (45). Whatever method is chosen, more important than stratification 
is ensuring that randomization is carried out in a rigorous manner. 
Sometimes an unequal randomization is used, for example, with a 2:1 or 3:2 ratio in favor 
of the new treatment (46). This has 2 possible advantages: it increases information on the new 
treatment (e.g., to allay safety concerns) and may also stimulate greater enthusiasm by 
investigators and patients knowing they have more than a 50-50 chance of getting the new 
treatment. For instance, the SYMPLICITY-HTN 3 trial of renal denervation versus a sham 
procedure in resistant hypertension had a 2:1 randomization ratio, whereas the HORIZONS-AMI 
trial in primary PCI had a 3:1 ratio of drug-eluting versus bare-metal stents (5,47). But there is a 
loss of statistical power with unequal randomization. For example, for 3:2, 2:1, and 3:1 ratios, 
the total number of patients needs to increase by 4.2%, 12.5%, and 33.3%, respectively, to 
preserve the same power as a trial with equal randomization. 
Blinding 
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It is standard practice for drug trials to be double-blind: that is, the patients and those 
responsible for their treatment and follow-up evaluation do not know which randomized 
treatment they are assigned (48,49). This is the optimal way to ensure that any potential 
influence that awareness of treatment might have on patient perceptions, patient management, 
and evaluation of endpoints is avoided.  
So what are we to make of trials that are not double-blinded? For instance, the 3-arm RE-
LY trial in atrial fibrillation compared 2 fixed doses of dabigatran in a blinded manner with 
open-label use of warfarin (15). Does this bias the comparison with warfarin? Having all primary 
and secondary outcome events adjudicated by an independent group who were centrally blinded 
helps reduce bias, but we are still reliant on unblinded patients and investigators to fairly report 
relevant events. Other similar trials; for example, the ARISTOTLE trial of apixaban vs. warfarin, 
were double-blinded, with the consequent complexity of carrying out repeat international 
normalized ratio testing on all patients, including those not on warfarin (50). Which of these 
approaches is better is open to debate. 
Of course, many trials of devices and alternative treatment strategies cannot possibly be 
double-blinded. For instance, the MATRIX trial of radial versus femoral access for ACS patients 
undergoing invasive management inevitably had patients and treating physicians aware of their 
randomized assignment, but outcome assessors were masked (blinded)(42). Such a PROBE 
(Prospective Randomized Open Blinded Endpoint) design is commonly used (51), but many 
researchers believe that the data obtained is less reliable than in a double-blind study. 
Blinding becomes particularly important when the primary endpoint is not on the basis of  
“hard” clinical events (with objective definitions), but on softer endpoints, such as quality of life 
indicators, or a measurement such as blood pressure. The SYMPLICITY HTN-3 trial in resistant 
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hypertension is an important illustration of the value of comparing a device (renal denervation) 
with a sham procedure. Both the patients and the blood-pressure assessors were unaware of the 
study-group assignments (47). In prior unblinded and uncontrolled studies, marked blood 
pressure lowering was attributed to renal denervation. In contrast, in the sham-controlled 
randomized trial, comparable reductions in blood pressure were noted in the treatment and 
control groups, suggesting a substantial placebo effect with some regression to the mean (52).  
The neutral finding of this trial, the first objective, unbiased evaluation of renal denervation, has 
importantly affected future trial design considerations for medical devices in general. 
Trial Size 
A key role of statistical reasoning in trial design is the provision of power calculations to 
determine the required trial size (53). Focusing on the trial’s primary endpoint, one needs to 
specify the expected event rate in the control group, the magnitude of treatment effect that the 
trial is required to detect (the alternative hypothesis), and the degree of certainty that such 
detection should occur (the statistical power: 1 minus the risk of a type II error [β] and the 
significance level that qualifies as “detected” [the risk of a type I error (α)]).  
For instance, in the CHAMPION-PHOENIX trial in patients undergoing PCI, the 
composite primary endpoint was death, MI, ischemia-driven revascularization, and stent 
thrombosis within 48 h. The investigators planned for a difference of 5.1% in patients treated 
with clopidogrel versus 3.9% in patients treated with cangrelor (a 24.5% relative risk reduction) 
to be detected with 85% power and type I error of 0.05. This required a total of 10,900 
randomized patients (5,450 per group). They actually recruited 11,145 patients and the observed 
difference was in fact 5.9% versus 4.7%, p = 0.005 (54). 
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Note the large sample size that was required. Had the trial planners hypothesized an 
unrealistic 50% relative risk reduction with 80% power, the required trial size would have been 
reduced to 1,780 patients. With observed rates of 5.9% versus 4.7% the p value would have been 
0.25, well short of statistical significance. Fortunately, such overoptimistic planning is becoming 
less common nowadays in major CV trials, although this requires commitment to relatively large 
trials, with modestly realistic, but still clinically important, expectations of treatment benefit. 
For chronic disease trials, sample size determination involves considering length of 
follow-up as well as patient numbers. For instance, the PARADIGM trial in chronic heart failure 
was planned to recruit 8,000 patients with a mean 34 months follow-up. For the composite 
primary endpoint of heart failure hospitalization and CV death, they anticipated an annual event 
rate of 14.5% on enalapril, and had 97% power to detect a 15% relative risk reduction on 
LCZ696, with type I error of 0.05. Why set the power so high? They also wanted good statistical 
power (80%) to also detect the same relative risk reduction in the secondary endpoint of CV 
death alone. A wise choice, in fact, because the published trial results showed marked treatment 
benefits for both outcomes (20). 
A cynical view of statistical power calculations is that people “juggle with the numbers” 
until they get the sample size they always wanted (or could afford). There is an element of truth 
to this: there are practical limits on what is achievable patient recruitment. Hence, some 
compromise is needed in not making the target so difficult as to put the consequent number of 
patients out of range for a real world study. 
So how can we “play with the numbers” while preserving scientific integrity? Take 
CHAMPION-PHOENIX as an example, and consider varying the parameters that feed into the 
calculations: 
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1. Control group event-rate. If one were to double the anticipated 5.1% rate to 10.2%, 
while keeping the same relative risk reduction and power, one could halve the required 
number of patients. But this would be an artificial deception, unless recruitment was 
restricted to very high-risk patients, an unrealistic option in this case. 
2. Alternative hypothesis. The required number of patients is inversely proportional to the 
square of the declared absolute treatment difference. So if one increased this difference 
from 5.1% (control) − 3.9% (treatment) = 1.2% to 5.1% − 2.7% = 2.4%, one would only 
need less than a quarter of the patients, that is, 2,400 rather than 10,900. In contrast, 
halving the difference to a mere 0.6% takes the sample size to a staggering 46,300 
patients. The declared 1.2% difference was a realistic compromise. 
3. Power. There is nothing magical about the chosen power. The greater the power, the 
larger the required patient numbers (but the smaller the likelihood of failing to detect a 
difference that is truly present). A common choice is 90% power: it carries a reasonable 
sense of guarantee that one would be unlucky (10% chance) to miss out on detecting the 
specified treatment difference, if it were true. If one reduces the power to 85% or 80%, 
then trial size can be reduced by 14% and 25%, respectively. Reducing power down to 
50% reduces sample size by 63% compared with 90% power, but only a gambler would 
take such a risk. Few trials are performed with <80% power. 
4. Type I error. One could choose options other than the conventional 0.05. For instance, 
changing to 0.1 or 0.01 would make trial size around 19% smaller and 42% bigger, 
respectively, but the former falls short of conventional significance and the latter is not 
commonly chosen. 
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An important fact when determining trial size is to recognize that statistical power 
depends mainly on the total number of patients in the trial experiencing the primary event during 
follow-up. Thus, some trials are event-driven, meaning that all patients are followed until that 
calendar date when the required number of events has occurred. Applying this logic, how many 
events should a trial aim for? A useful approximate formula is the following: one declares the 
hazard ratio (or risk ratio) for the alternative hypothesis and its associated statistical power (1− β) 
(often 90% or 80%) and the 2-sided type I error (α) (usually 0.05). Then, the total events 
required: 
  
      
      
 × f(α, β) 
where f(α, β) =          
 
, which equates to 10.51 and 7.85 for 90% and 80% power, 
respectively, with α = 0.05. z is a standardized normal deviate. 
Thus, if one wishes to detect a hazard ratio of 0.7 (i.e., a 30% relative risk reduction) with 
80% power, then 252 total primary events are required. A much tougher challenge is to detect a 
hazard ratio of 0.85 (i.e., a 15% relative risk reduction) with 90% power because this requires a 
total of 1,194 primary events. 
Figure 2 displays the power curves to assist the reader in determining their own trial size 
(required number of events) for any choice of hazard ratio, with options for 90% and 80% power, 
as desired. 
It has been argued that all power calculations enforce an arbitrary logic by focusing on a 
particular alternative hypothesis. In practice, the trial statistician could produce extensive 
tabulations by varying all 4 of the above parameters, thus guiding the investigators to a sensible 
trial size. Overall, a concise logic, specified in both the trial protocol and the publications’ 
Methods section, helps to instill confidence that the trialists chose wisely (and achieved) their 
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target sample size. Of course, “the bigger the better” is a crude maxim whereby the larger the 
trial becomes, the greater the precision of any treatment effect estimate (and the more likely are 
the results to approximate “the truth”). This scientific optimization always needs to be placed in 
perspective alongside the need to keep the trial’s scale, duration, and costs finite. 
Concluding Remarks 
A sound knowledge of the essential issues in the design of major randomized trials, as 
outlined in this paper, is of importance to cardiologists and others involved in trials research and 
their interpretation. Although there are many details of relevance, the essential elements of 
designing a worthwhile investigation include: 
1. Identifying a valuable therapeutic concept worthy of a major trial; 
2. Focusing on the essentials of the trial protocol: defining exactly which patients, which 
treatment comparison(s) and which primary (and secondary) endpoints should be studied; 
3. Ensuring the trial provides a reliable (unbiased) treatment comparison by appropriate 
randomization, blinding and quality delivery of the protocol’s intent; 
4. Making the trial large enough so that it is adequately powered to detect (or refute) any 
treatment differences of clinical importance. 
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FIGURE LEGENDS 
Central Illustration: Fundamentals of Design of Major Randomized Controlled Trials 
Figure 1: Geographic Disparities in the TOPCAT Trial’s Results for the Primary Endpoint 
(cardiovascular death and heart failure hospitalization). 
Figure 2: Total Number of Primary Events Needed to Detect a Specific True Hazard Ratio 
as Statistically Significant (α = 0.05). 
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Table 1: Key Issues Regarding Composite Endpoints 
Considerations Discussion 
Statistical power 
 
For adequate power, trials with a single endpoint may be too 
large to be practical. 
Including several endpoints increases event frequency and may 
increase power. 
Selecting components of 
the composite 
A single endpoint may not fully document treatment effect. 
Composite endpoint captures several clinical aspects. 
Choose components so overall effect is meaningful. 
Evaluating treatment 
effect 
Interpretation can be difficult: 
 - Components may differ in clinical importance. 
 - Impact of treatment may vary across components. 
It is best to have separate safety and efficacy endpoints. 
Analysis considerations Emphasis usually on time to first event, which is often less 
serious (e.g., hospitalization) than subsequent events (e.g., 
death). 
Always show results for each separate component. 
Methods exist for repeat events and for competing risks, but 
complexity is a challenge. 
Win Ratio method prioritizes events of greater clinical 
importance. 
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Table 2: Key Issues Regarding Randomization Methods 
 Discussion 
Allocation concealment Ensure treatment assignment cannot be predicted in advance of 
patient entry. 
Double-blind Patients, investigators, and those evaluating outcome remain 
unaware of assigned treatment after randomization. 
Single-blinding Investigators (and possibly patients) are aware of the assigned 
treatment, whereas those evaluating outcomes remain blinded. 
Superior to an unblinded design, but introduces greater 
opportunities for bias than a double-blind design. 
Methods of 
randomization 
 
Simple randomization Like coin tossing, with no connection between allocations. 
May lead to treatment imbalance in numbers or key patient 
factors. 
Random permuted blocks Treatment numbers are equal after each block of patients. 
Order of treatments within each block is random. 
Block sizes may vary to avoid predictability if trial not double-
blinded. 
Stratification Aims to ensure balance for key patient factors across treatment 
groups. 
Each combination of factors (e.g., center and sex) has its own 
random permuted blocks. 
Must avoid over-stratification (e.g., 4 binary factors = 16 strata), 
which may introduce imbalances. 
Minimization A dynamic approach.  
Each treatment allocation done to achieve the best balance across 
several patient factors. 
Unequal randomization Can allocate more patients on new treatment (e.g. 2:1 ratio). 
Increases knowledge of new treatment and may enhance 
investigator/patient enthusiasm 
Requires more patients. 
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